News | February 17, 2025
Nectar Life Care launches affordable anti-diabetic range of medicines
Offers affordable, high-quality solutions for diabetes care
Offers affordable, high-quality solutions for diabetes care
Plans underway to expand screening capacity by 50% for greater accessibility
Cancer cases in India estimated to reach 1.57 million in 2025
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Subscribe To Our Newsletter & Stay Updated
